Morgan Stanley
TLIS

Morgan Stanley’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Morgan Stanley’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-87
Closed -$754 – 8093
2024
Q2 		$754 Sell
87
-548
-86% -$4.86K ﹤0.01% 7186
2024
Q1 		$5.56K Sell
635
-107
-14% -$882 ﹤0.01% 6867
2023
Q4 		$5.53K Sell
742
-1,519
-67% -$9.9K ﹤0.01% 6983
2023
Q3 		$13K Sell
2,261
-1,863
-45% -$12.7K ﹤0.01% 6630
2023
Q2 		$29.7K Buy
4,124
+67
+2% +$486 ﹤0.01% 6414
2023
Q1 		$29.8K Buy
4,057
+84
+2% +$714 ﹤0.01% 6477
2022
Q4 		$26.6K Sell
3,973
-1,319
-25% -$11.6K ﹤0.01% 6556
2022
Q3 		$54K Sell
5,292
-6,151
-54% -$77.8K ﹤0.01% 6375
2022
Q2 		$139K Buy
11,443
+1,423
+14% +$22.5K ﹤0.01% 6096
2022
Q1 		$212K Sell
10,020
-1,736
-15% -$60.1K ﹤0.01% 5889
2021
Q4 		$708K Sell
11,756
-9,218
-44% -$690K ﹤0.01% 5327
2021
Q3 		$1.97M Sell
20,974
-8,509
-29% -$1.13M ﹤0.01% 4600
2021
Q2 		$4.88M Buy
29,483
+28,331
+2,459% +$4.81M ﹤0.01% 3802
2021
Q1 		$222K Buy
+1,152
New +$287K ﹤0.01% 5605

Other funds holding TLIS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Morgan Stanley's TLIS Position: Q3 2024 in Review

Morgan Stanley sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2024, closing a stake of 87 shares — an estimated $754 sold.

Morgan Stanley first reported a position in TLIS in Q1 2021 and held it in 14 quarters. The position peaked at $4.88M in Q2 2021. 2 funds tracked by Wall St. Rank hold TLIS as of Q3 2024.

  • Morgan Stanley reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2024 after selling out during the quarter.
  • Morgan Stanley sold 87 Talis Biomedical Corporation Common Stock shares in Q3 2024, an estimated $754.
  • Morgan Stanley first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 14 quarters.
  • Morgan Stanley's Talis Biomedical Corporation Common Stock position peaked at $4.88M in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2024.

Based on Morgan Stanley's 13F filing for Q3 2024, filed 14 Nov 2024.